Asia-Pacific: Expected to witness rapid growth driven by increasing investments in biotechnology research, expanding healthcare facilities, and supportive government initiatives.
Genome Editing Market Recent Developments
In January 2024, Danaher Corporation partnered with the Innovative Genomics Institute (IGI).
In November 2023, Selectis signed a collaboration agreement with AstraZeneca to accelerate the development of advanced therapies in oncology and immunology.
In July 2023, Sangamo Therapeutics partnered with Chroma Medicine to develop epigenetic drugs using Sangamo’s zinc finger proteins (ZFPs).
Top Players in Genome Editing Market
Merck KGaA (Germany)
Cibus Inc (US)
Recombinetics (US)
Sangamo Therapeutics (US)
Editas Medicine (US)
Precision BioSciences (US)
CRISPR Therapeutics (Switzerland)
Intellia Therapeutics, Inc (US)
Caribou Biosciences, Inc. (US)
Cellectis S.A (France)
AstraZeneca (UK)
Takara Bio Inc. (Japan)
Danaher Corporation (US)
Transposagen Biopharmaceuticals, Inc. (US)
Genscript Biotech Corp (China)
New England Biolabs (US)
OriGene Technologies, Inc. (US)
Lonza (Switzerland)
Thermo Fisher Scientific Inc. (US)
Future Outlook:
The genome editing market is anticipated to continue its robust growth trajectory, fueled by technological advancements, expanding therapeutic applications, and increasing acceptance of
personalized medicine. Ethical considerations and regulatory frameworks will play a crucial role in shaping the future landscape of genome editing technologies.
For a comprehensive analysis, refer to the full report by SkyQuest Technology: https://www.skyquestt.com/report/genome-editing-market
